NeuroEndocrine Cancer Australia at ENETS 2025: Advancing NET Care on the Global Stage
NeuroEndocrine Cancer Australia (NECA) proudly represented Australia at the 22nd Annual European Neuroendocrine Tumour Society (ENETS) Conference, held from 5–7 March 2025 in Kraków, Poland. This event brought together leading clinicians, researchers, and patient advocacy groups from around the world to discuss the latest advancements in neuroendocrine tumour (NET) care, research, and policy.
NECA’s participation ensured that the voices of Australian patients were heard on a global stage. The conference featured cutting-edge presentations on emerging treatments, advancements in diagnostic imaging, and developments in precision medicine tailored for NET patients.
NECA CEO Meredith Cummins, who is also an INCA Board Director and Chair of the INCA Research Committee, outlined examples of NET patient advocates partnering with researchers both locally and internationally. She highlighted how the local best practice comes from NeuroEndocrine Cancer Australia and emphasised INCA’s activities for global interaction between patient advocates and NET investigators. Meredith also presented key projects aimed at preparing informed research advocates across the globe, reinforcing the importance of patient involvement in advancing NET research and treatment.
Meredith, along with 9 other NET specialists from Australia, engaged with international experts to share insights into the challenges faced by Australian NET patients, including access to treatments, diagnostic delays, and the need for greater investment in research. A key focus was advocating for equitable access to life-changing therapies and ensuring that Australia remains aligned with international best practices in NET management.
One of the highlights of the conference was the discussion around patient-centred care and the importance of multidisciplinary approaches in improving patient outcomes. NECA also took the opportunity to strengthen collaborations with global counterparts to drive forward initiatives that enhance support for NET patients worldwide.
“The ENETS conference is an invaluable opportunity for us to stay at the forefront of NET care, ensuring that Australian patients benefit from the latest research and treatment advancements,” said Meredith Cummins, CEO of NECA. “By engaging with international experts, we continue to advocate for improved patient outcomes and access to treatments in Australia’s healthcare landscape for NET patients.”
Find out more about all the presentations during the INCA/ENETS session at the 22nd European Neuroendocrine Tumor Society e.V. (ENETS) Conference in Krakow: click here
